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Abstract
To date, over 150 disease-associated variants in CRB1 have been described, resulting in a range of retinal disease phenotypes
including Leber congenital amaurosis and retinitis pigmentosa. Despite this, no genotype–phenotype correlations are
currently recognised. We performed a retrospective review of electronic patient records to identify patients with macular
dystrophy due to bi-allelic variants in CRB1. In total, seven unrelated individuals were identified. The median age at
presentation was 21 years, with a median acuity of 0.55 decimalised Snellen units (IQR= 0.43). The follow-up period
ranged from 0 to 19 years (median= 2.0 years), with a median final decimalised Snellen acuity of 0.65 (IQR= 0.70).
Fundoscopy revealed only a subtly altered foveal reflex, which evolved into a bull’s-eye pattern of outer retinal atrophy.
Optical coherence tomography identified structural changes—intraretinal cysts in the early stages of disease, and later outer
retinal atrophy. Genetic testing revealed that one rare allele (c.498_506del, p.(Ile167_Gly169del)) was present in all patients,
with one patient being homozygous for the variant and six being heterozygous. In trans with this, one variant recurred twice
(p.(Cys896Ter)), while the four remaining alleles were each observed once (p.(Pro1381Thr), p.(Ser478ProfsTer24), p.
(Cys195Phe) and p.(Arg764Cys)). These findings show that the rare CRB1 variant, c.498_506del, is strongly associated with
localised retinal dysfunction. The clinical findings are much milder than those observed with bi-allelic, loss-of-function
variants in CRB1, suggesting this in-frame deletion acts as a hypomorphic allele. This is the most prevalent disease-causing
CRB1 variant identified in the non-Asian population to date.
Introduction
To date, more than 150 disease-associated variants in CRB1
(OMIM #604210) have been described, associated with a
range of inherited retinal disease (IRD) phenotypes
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including Leber congenital amaurosis (LCA), early as well
as adult-onset retinitis pigmentosa (RP)—with and without
a Coats-like vasculopathy, and more recently macular dys-
trophy and foveal schisis [1–11]. Characteristic features of
CRB1-associated retinopathy include early onset maculo-
pathy, loss of retinal lamination with increased retinal
thickness, nummular intraretinal pigmentation, preservation
of the para-arteriolar retinal pigment epithelium, and the
presence of macular cysts [12]. Expression of the retinal
phenotype, however, is variable, even within families, and a
number of either genetic or environmental factors have been
postulated [13].
CRB1, a human homologue of the Drosophila melano-
gaster gene crumbs (crb), is expressed in the foetal brain and
the inner segments of photoreceptors in humans [2, 14]. It
consists of 12 alternatively spliced exons, resulting in two
different transcripts of 1376 and 1406 amino acids. Both
contain extracellular domains (19 epidermal growth factor
(EGF)-like domains, three laminin A globular (AG)-like
domains and a signal peptide), but the longer isoform addi-
tionally contains transmembrane and cytoplasmic domains
(FERM-binding domains and a PDZ-binding motif), which
facilitate assembly of adherens junction complexes and
linking to the actin cytoskeleton [15, 16]. Consequently,
CRB1 has been implicated in mechanisms that control cell
adhesion, polarity and intracellular communication, and is
considered crucial for photoreceptor morphogenesis and
subsequent function [17–19]. In the developing retina, core
Crumbs complex proteins localise to the apical side of the
epithelium, which will ultimately form the junction between
photoreceptor cells and Müller glia, constituting the external
limiting membrane (ELM) [14, 20, 21].
To date, no genotype–phenotype correlations have been
identified, and a comprehensive understanding of CRB1
function is still sought. This study aims to make advances in
this field, presenting novel clinical data describing a specific
consequence of the CRB1 variant c.498_506del.
Materials and methods
Subjects and clinical assessment
Patients known to the eye clinic at one of two hospitals
(Moorfields Eye Hospital, London and St. James’s Uni-
versity Teaching Hospital, Leeds) with a diagnosis of
macular dystrophy and at least one variant in CRB1 were
identified using in-house databases (OpenEyesTM, London
and MedisoftTM, Leeds). Initial searches did not select for
bi-allelic variants only to ensure any cases with missing
second alleles were not filtered out. Electronic healthcare
records and case notes were then reviewed. Patients had
been diagnosed by one of the authors on the basis of slit
lamp examination and imaging studies including colour
fundus photography (Topcon TRC-NW400, Topcon,
Japan), spectral domain optical coherence tomography (SD-
OCT) and fundus autofluorescence (FAF) (Spectralis HRA
and OCT system, Heidelberg Engineering, Heidelberg,
Germany). Electroretinography was performed incorporat-
ing the International Society of Clinical Electrophysiology
of Vision (ISCEV) standards, and included full-field elec-
troretinogram (ERG), pattern electroretinogram (PERG) and
electro-oculogram (EOG) [22, 23].
Next-generation sequencing
Molecular testing was performed either by targeted next-
generation sequencing (National Genetics Reference
Laboratory, Manchester, UK or Yorkshire Regional Genet-
ics, Leeds, UK), or as part of a national collaborative whole-
genome sequencing project (NIHR BioResource Rare Dis-
eases Study) [24, 25]. Segregation studies were performed,
where additional family members were available. All patients
had previously provided informed consent as part of a
genetics research project approved by the local research
ethics committee, and all investigations were conducted in
accordance with the principles of the Declaration of Helsinki.
All CRB1 variants reported in this paper have been deposited
into the ClinVar database at the National Centre for Bio-
technology Information under accession numbers ClinVar:
SCV000611552-SCV000611557.
Identification of additional patient
Our search for additional patients who were homozygous for
the in-frame deletion (c.498_506del) identified one further
individual from the Diagnostic Centre of Bartiméus, Zeist, the
Netherlands. In this patient, OCT was performed with Cirrus
high definition (Carl Zeiss Meditec, Inc, Dublin, CA), FAF
with Canon CX-1 Digital retinal camera (Canon Inc. Shimo-
maruku 3-CHOME Ohta-Ku, Tokyo, Japan). Electro-
physiological examinations included full-field ERG, EOG and
multifocal ERG, all according to ISCEV standards [22, 23].
Mutation analysis was performed at the Academic Medical
Centre, Amsterdam by targeted next-generation sequencing.
Results
Seven unrelated individuals were identified with a macular
dystrophy due to suspected bi-allelic variants in CRB1. No
patients with single, heterozygous variants in CRB1 were
knowingly excluded. All patients were of European ances-
try and from non-consanguineous pedigrees. In six out of
the seven cases, only a single affected family member was
identified. MEH3 was the exception, as two great paternal
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A clinical and molecular characterisation of CRB1-associated 689
uncles had been diagnosed with presumed autosomal
recessive, severe, early onset RP, but had not undergone
genetic testing.
At presentation, patients were either asymptomatic, and
their disease was discovered by their optometrist (Leeds 1,
MEH3 and BDC6), or they were aware of a change in the
quality of their central vision, and actively sought medical
attention. No patients reported symptoms that were
consistent with night blindness or peripheral field loss.
Patients presented with bilateral disease in all cases; how-
ever, the functional consequences were occasionally
asymmetrical (Table 1). The median age at presentation was
21 years (IQR= 19), associated with a median visual acuity
of 0.55 decimalised Snellen units (IQR= 0.43). Six of the
seven patients were reviewed more than once, with follow-
up ranging from 1.5 to 19 years. By the final visit, the
Fig. 1 Optical coherence
tomography and fundus
autofluorescence imaging of
patients with CRB1-associated
maculopathy. a Optical
coherence tomography (OCT)
line scans with near infra-red
reflectance images showing scan
position (inset). Macro and
microcystic oedema is evident in
patients MEH1, 2 and BDC6.
Foveolar preservation of the
ellipsoid zone is present in
MEH1, MEH2, Leeds 1 and
BDC6. More significant
degeneration has already
occurred in MEH3 and 4,
including loss of the external
limiting membrane and outer
nuclear layers. Varying degree
and extent of macular thickening
and loss of lamination is evident
in MEH3, 4 and 5. b Fundus
autofluorescence images from
the same time point as OCT
scans. Macular autofluorescence
is abnormal in all cases, but
again with a degree of foveolar
sparing. In the oldest patients,
the zone of abnormal
autofluorecence extends to
include the peripapillary retina
—initially an increase in signal
(Leeds 1), which is likely to
evolve to reduced (MEH4) and
then lost autofluorescence
(MEH3 and 5)
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median acuity was 0.65 decimalised Snellen units (IQR=
0.70). Over the follow-up period, only two eyes (two
patients, MEH2 and 5) recorded a minimal loss of acuity.
Across the group, however, older patients tended to have
poorer visual function than younger ones (Table 1).
SD-OCT scans identified anatomical changes in all cases
(Fig. 1). In the three youngest patients (MEH1, 2 and
BDC6), intraretinal cysts were evident in the inner and outer
nuclear layers (INL, ONL), a feature that was less apparent
with increasing age. In older patients (Leeds 1, MEH3, 4
and 5), there was evidence of outer retinal degeneration and
macular atrophy. This initially appeared to spare the
foveola, preferentially affecting the perifoveal retina,
resulting in a bull’s-eye maculopathy phenotype (Fig. 1).
Three patients showed varying degrees of retinal thickening
and loss of physiological lamination (MEH3, 4 and 5)
(Fig. 1). No patients had evidence of significant progressive
choroidal thinning. Macular autofluorescence was abnormal
in all patients (Fig. 1 and Table 1). The peripheral retina
however retained physiological levels of autofluorescence,
although in the oldest patients (Leeds 1, MEH3, 4 and 5) the
hyper-autofluorescent signal extended nasal to the optic disc
(Fig. 1).
Macular dysfunction was present in all cases, with either
low amplitude P50 PERG (n= 6) or central mfERG
waveforms (n= 1). No full-field ERG or EOG abnormal-
ities were observed.
Genetic testing identified two disease-causing variants in
all patients. Six shared a rare, single allele resulting in an in-
frame deletion of three amino acids (NM_201253.2:
c.498_506delAATTGATGG, NP_957705.1:p.(Ile167_-
Gly169del)) previously associated with disease
(rs398124615) [9, 10, 26, 27]. The trans-acting variants in
each case were predicted to result in either a missense (p.
(Cys195Phe), p.(Arg764Cys) or p.(Pro1381Thr)) or a pre-
mature termination codon (p.(Cys896Ter), p.(Ser478Prof-
sTer24)) (Table 1). Patient BDC6 was homozygous for the
in-frame deletion (c.498_506del, p.(Ile167_Gly169del)).
Discussion
The present work describes seven patients with isolated
macular disease consequent upon bi-allelic variants in
CRB1, six of whom are heterozygous for one rare allele
(c.498_506del, p.(Ile167_Gly169del)), and one patient who
is homozygous. These findings provide the first evidence of
a genotype–phenotype correlation in CRB1-associated reti-
nopathy, and that in humans the subtlest sign of CRB1
dysfunction is confined to the posterior pole, centred on the
macula, that intriguingly initially spares the foveola.
Isolated macular disease is a recently identified and rare
consequence of variants in CRB1 (Supplementary Table 1)
[7–10]. The underlying genotypes are summarised in Sup-
plementary Tables 1 and 2. Of all, CRB1 alleles identified to
date that affect protein function, the most prevalently
reported in IRD cohorts is p.(Cys948Tyr) (rs62645748)2,
for which the carrier frequency in the general population is
0.041% (56/276,322 alleles, gnomAD Browser, accessed
1.6.17), and 0.08% in Europeans (50/56 alleles are Eur-
opean). The variant that is the focus of this study,
p.(Ile167_Gly169del), is in fact over 1.5 times more com-
mon, with a population prevalence of 0.124% (173/277,040
gnomAD Browser, accessed 1.6.17), and again the majority
are Europeans alleles (125/173). This variant has never been
associated with LCA, and has only been identified in
patients with relatively less severe forms of generalised
retinal disease (Supplementary Table 2). Its presence
has also been used to explain the milder retinopathy evident
in one member of a pedigree harbouring three separate
CRB1 alleles—the individual with early onset RP (III:6)
was homozygous for p.(Cys948Tyr), while her sister
(III:4), who exhibited late-onset disease and a slower
progression, carried the in-frame deletion (p.(Ile167_-
Gly169del)) paired with p.(Cys948Tyr) [27]. The present
data, together with that already published, provide a per-
suasive argument that this in-frame deletion acts as a
hypomorphic allele.
Opposing this hypothesis is a prior report of a patient
(RP-1426) homozygous for p.(Ile167_Gly169del), but
associated with an 'early-onset RP' phenotype [26]. No
further clinical details were presented, and it is unknown if
this individual harbours additional genetic variants that
contribute to the phenotype. Motta et al. also identified a
patient harbouring this allele, with an apparently syndromic
form of disease (Patient 14—nyctalopia, myopia, glaucoma
and hearing loss). As the second, convincingly disease-
causing variant remains elusive, it remains uncertain if
c.498_506del contributes to this phenotype at all [28]. The
gnomAD database (accessed 1 June 17) additionally con-
tains one further individual who is homozygous for this in-
frame deletion. As data from individuals with severe, con-
genital paediatric disorders are excluded from gnomAD,
this suggests that here at least this genotype is not asso-
ciated with LCA. While the degree of overall CRB1 dys-
function is highly likely to influence the ensuing
retinopathy, as recently suggested by Motta et al. [28], our
data suggest, for the first time, that specific alleles are able
to exert a strong influence on the phenotype. In an attempt
to clarify the clinical consequences associated with this
genotype, this work provides a detailed characterisation of
one individual who is homozygous for the c.498_506del
variant (BDC6). In this individual at least, this genotype is
associated with later-onset (i.e., not infantile-onset), isolated
macular disease. When the same variant is paired with a null
allele (e.g., in MEH2 and 3), a similarly limited form of
A clinical and molecular characterisation of CRB1-associated 691
disease ensues. As null alleles have never previously been
associated with isolated macular disease (Supplementary
Table 1), it is likely that this phenotype is determined by the
hypomorphic, trans-acting variant (Supplementary
Table 2). Additional genetic modifying factors may also
exist, which could include those in CRB2, as rescue of the
retinal phenotype in Crb1 knockout mice has recently been
demonstrated using AAV-Crb2 gene therapy [29]. As
CRB1 is only one member of a larger, multimeric protein
complex that includes other transmembrane proteins
(CRB2, CRB3), which physically interact with a number of
cytoplasmic proteins (MPP5/PALS1, PATJ, MUPP-1,
MPP3 and MPP4), dysfunction in any one of these could
potentially contribute to the disease phenotype [7, 30–33].
The recent discovery that bi-allelic variants in CRB2 results
in syndromic disease, and that retinal dysfunction is iden-
tified in a minority of these patients is in keeping with the
above hypothesis [34–36].
Other hypomorphic alleles are also likely to exist and
Supplementary Table 2 highlights two further examples.
Both variants (p.(Gly123Cys) and p.(Arg1331Cys)) intro-
duce a cysteine residue into different EGF-like domains of
CRB1. These motifs are characterised by the presence of six
highly conserved cysteines, resulting in three pairs of dis-
ulphide bridges; introducing a seventh residue is likely to
induce structural change, reducing steric flexibility. The
specific location where this occurs will determine the
overall effect on tertiary structure, the subsequent binding
affinity with other CRB-complex proteins and ultimately the
disease phenotype. It is also tempting to speculate that
further alleles with intermediate pathogenicity also exist—
somewhere between those associated with the in-frame
deletion and those that are functionally null. In keeping with
this hypothesis, when observed in the homozygous state,
both p.(Pro836Thr) and p.(Ser740Phe) appear to cause
macular dysfunction, but with additional selective impair-
ment of peripheral cones, sparing peripheral rod photo-
receptors [8, 13]. It is likely therefore that an allelic
hierarchy exists, and that detailed clinical phenotyping will
enable this order to be established.
The phenotypes associated with the in-frame deletion p.
(Ile167_Gly169) as well as other, 'mild' variants in CRB1 are
also intriguing [6, 7, 9, 10, 26]. First, 'cystic' cavities in the
ONL and INL are observed as an early feature of disease.
These may be associated with either a qualitative or quan-
titative reduction in acuity, which appears to fluctuate as the
disease evolves (MEH1). It is pertinent to note that intrar-
etinal cysts are also a prominent feature of another disorder
strongly associated with Müller cell dysfunction—Macular
Telangiectasia (MacTel) [37]. A spontaneously arising rat
model for MacTel exists, also shown to harbour a homo-
zygous in-frame deletion in Crb1, which results in a limited,
macular phenotype [38]. Second, although early macular
atrophy is a feature of CRB1-associated LCA, the mildest
form of disease appears to spare the foveola, presenting as a
bull’s-eye maculopathy (Leeds 1, MEH3). Why the disease
evolves in this pattern is unknown, but it may relate to
structural or metabolic differences between foveolar cones
and their parafoveal neighbours. Alternatively, a bull’s-eye
pattern of degeneration may be determined by Müller cells,
as they too exhibit regional differences in structure. This
pattern of degeneration again is observed in the initial stages
of MacTel, where the earliest changes of disease are evident
temporal to, and not at, the fovea [37]. Third, the extent of
retinopathy in the oldest patients appears not to be anato-
mically limited to the macula, as the retina superior, inferior
and nasal to the optic nerve is also affected (Fig. 1). This is
an unusual and infrequently encountered pattern of degen-
eration, but one that is shared with other monogenic reti-
nopathies, where the underlying gene regulates cell–cell
adhesion (ADAM9, CDH3) [39, 40]. Fourth, retinal thick-
ening and loss of lamination may be evident, another phe-
notypic clue suggestive of CRB1-associated retinopathy
[41]. Lastly, although not a feature of patients in this series,
two independent groups have identified patients with CRB1
variants and subtle full-field ERG abnormalities, with mild
dysfunction evident in cone photoreceptors [8, 10]. If mild
dysfunction in CRB1 is associated with localised disease at
the macula/posterior pole, then alleles of slightly greater
pathogenicity may additionally disrupt peripheral cone, but
not rod, function. The most severe variants however result in
early and widespread loss of both types of photoreceptors.
In summary, we describe the phenotypic consequences of
bi-allelic variants in CRB1, where one allele is c.498_506del,
p.(Ile167_Gly169del), and the phenotype of one individual
homozygous for this variant. This is the most prevalent
disease-causing CRB1 variant identified in the non-Asian
population to date. It is more likely to result in localised rather
than generalised retinal dysfunction, and so consequently is
associated with a better clinical prognosis, as seen in this
study. Understanding how genetic variation in CRB1 con-
tributes to patients’ retinal phenotype will become increasingly
important as we continue to develop therapies, and search for
biomarkers that will be useful in monitoring response.
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